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Abstract
Background: Irritable Bowel Syndrome (IBS) is a disorder characterized by abdominal pain or
discomfort associated with changes in bowel habit. Currently there are no objective outcome
measures for evaluating the effectiveness of treatments for this disorder.
Aims: To determine the usefulness of a method of analysis that employs polar vectors to eval-
uate the effectiveness of IBS treatments.
Methods: Data from a Phase IV clinical study with 1677 active IBS-Rome III patients who received
100mg of pinaverium bromide + 300mg of simethicone (PB + S) po bid for a period of four weeks
were used for the analysis. Using the Bristol Stool Scale as a reference, the consistency and
frequency of each type of bowel movement were recorded weekly in a Bristol Matrix (BM) and
the data were expressed as polar vectors.
Results: The analysis showed a differential response to the PB + S treatment among the IBS
subtypes: in reference to the IBS with constipation subtype, the magnitude of the vector
increased from 10.2 to 12.5, reaching maximum improvement at two weeks of treatment
(p < 0.05, Scheffé). In the IBS with diarrhea and mixed IBS subtypes, the magnitude of the
vector decreased from 19 to 14 (p<0.05) and from 16.5 to 13 (p < 0.05), respectively, with con-
tinuous improvement for a period of four weeks. There was no deﬁnable vectorial pattern in
the unsubtyped IBS group.
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Conclusions: Analysis with polar vectors enables treatment response to be measured in differ-
ent IBS subtypes. All the groups showed improvement with PB + S, but each one had its own
characteristic response in relation to vector magnitude and direction. The proposed method
can be implemented in clinical studies to evaluate the efﬁcacy of IBS treatments.
© 2012 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
rights reserved.
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Vectores polares como método para evaluar la eﬁcacia de tratamientos para el
síndrome de intestino irritable: análisis con bromuro de pinaverio 100mg más
simeticona 300mg po bid
Resumen
Antecedentes: El Síndrome de Intestino Irritable (SII) es un trastorno caracterizado por dolor
o malestar abdominal, asociado a cambios en el hábito intestinal. Actualmente no existe una
variable objetiva para evaluar la eﬁcacia de los tratamientos para este trastorno.
Objetivo: Determinar la utilidad de un método de análisis con vectores polares para evaluar la
eﬁcacia de los tratamientos para el SII.
Métodos: Para el análisis, se utilizaron los datos de un estudio clínico fase iv con 1,677 pacientes
SII-Roma III, que recibieron bromuro de pinaverio 100mg + simeticona 300mg (BP + S) po bid
por 4 semanas. Se registraron semanalmente la consistencia y la frecuencia de cada tipo de
evacuación en una Matriz de Bristol (MB) y los datos se representaron como vectores polares.
Resultados: El análisis mostró una respuesta diferencial de los subtipos de SII al BP + S: en SII-
estren˜imiento, la magnitud vectorial se incrementó de 10.2 a 12.5, alcanzando una mejoría
máxima a las 2 semanas de tratamiento (p < 0.05 prueba de Schefé). En SII-diarrea y SII-mixto,
la magnitud del vector disminuyó de 19 a 14 (p < 0.05) y de 16.5 a 13 (p < 0.05), respectivamente,
con mejoría continua durante las 4 semanas. En SII-no clasiﬁcable no existió un patrón vectorial
deﬁnido.
Conclusiones: El análisis con vectores polares permite medir la respuesta a tratamiento en
los diferentes subtipos del SII. Todos los subtipos mostraron mejoría con BP + S, pero cada uno
respondió en forma característica en magnitud y dirección del vector. El método propuesto
puede ser implementado en estudios clínicos para evaluar la eﬁcacia de los tratamientos para
el SII.
© 2012 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
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ntroduction
rritable bowel syndrome (IBS) is a functional gastrointesti-
al disorder characterized by abdominal pain or discomfort
ssociated with changes in bowel habit.1 Based on the pre-
ominant bowel habit, it is classiﬁed into subtypes that, in
ccordance with the most recent Rome III2 criteria, are IBS
ith diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M),
nd unsubtyped (IBS-U).2
In the absence of a biological marker in IBS, diagnosis
s based on the Rome III1 clinical criteria that have been
eveloped to classify functional gastrointestinal disorders
FGIDs)2; but there are no objective outcome measures
or evaluating the efﬁcacy of treatments for this disor-
er. Regulatory agencies have recently shown an interest
n deﬁning such objective outcome measures for the clinical
rials that evaluate the medications presently being devel-
ped for IBS.3,4 The evaluation of pharmacologic efﬁcacy
ust encompass several aspects, including the intensity of
ardinal symptoms (abdominal pain and/or bloating) that
an be evaluated with a visual analog scale (VAS), as well as
hanges in bowel habit (e.g. stool consistency that can be
valuated using the Bristol Stool Scale, or stool frequency
hat can be analyzed through symptom diaries).3
i
i
g
pThe Bristol Stool Scale has been recommended by the
ome III committee.1 It is a tool that enables bowel move-
ents to be classiﬁed into seven categories, according to
onsistency: type 1, separate hard lumps, like nuts (hard
o pass); type 2, sausage-shaped but lumpy; type 3, like a
ausage but with cracks on the surface; type 4, like a sausage
r snake, smooth and soft; type 5, soft blobs with clear-
ut edges; type 6, ﬂuffy pieces with ragged edges, a mushy
tool; and type 7, watery, no solid pieces, entirely liquid.1 A
atrixial table or Bristol Matrix (BM) can be constructed by
imultaneously recording the changes in consistency using
he Bristol Stool Scale and measuring evacuation frequency.
his matrix integrates the two variables (omnibus variable)
nd can serve as an efﬁcacy measure for evaluating pharma-
ologic treatments for IBS. Data from the BM can be graphed
s a series of points or vectors in a two-dimensional space. In
esponse to treatment effectiveness, improvement in stool
requency and consistency (type) recorded in the BM will
e reﬂected as a movement of the vectors, and depending
n the IBS subtype, this movement can be in the same or
n opposite directions. For example, in patients with IBS-C,
mprovement means diminishing in evacuation consistency,
oing from a Bristol type 1 or 2 to a type 3 or higher, accom-
anied by increased evacuation frequency (moving from left
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Figure 1 Improvement of abdominal pain and bloating in rela-
tion to the Bristol Matrix. A scale that corresponds to stool
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mconsistency measured by the Bristol Stool Scale is shown. For
IBS-C, improvement should be from left to right, whereas for
IBS-D and IBS-M it should be from right to left.
to right, Fig. 1). In contrast, in patients with IBS-D, clinical
improvement implies bowel movements of a greater consis-
tency, going from types 6 and 7 to type 5 or lower, with a
reduction in evacuation frequency. Once the magnitude and
direction of the vectorial movement is known (the degree of
improvement), vectors can be transfered to a plane of polar
coordinates that enables the treatment response in all the
IBS subtypes to be observed at the same time. This method
of analysis is based on the assumption that things are more
easily understood if they can be visualized.
The aim of this study was to determine the usefulness of
the method of analysis employing polar vectors for evalu-
ating IBS pharmacologic treatment efﬁcacy. The data used
were obtained in an open Phase IV study conducted on
patients with active IBS who received 100mg of pinaverium
bromide + 300mg of simethicone (PB + S) po bid over a four-
week period. The hypothesis stated that this method is
adequate for evaluating the efﬁcacy of any IBS treatment,
by determining stool consistency and frequency improve-
ment through a BM that allows for the treatment response
in the various IBS subtypes (IBS-D, IBS-C, IBS-M, IBS-U) to be
differentiated.
Methods
Population
The data used in this analysis were obtained from a Phase IV
clinical study that included 1677 patients with active IBS in
accordance with Rome III criteria. Patients were recruited
by 1303 physicians with different specialties throughout the
Mexican Republic. Selection criteria were:
(a) For inclusion -- Patients of both sexes who were ≥18
and ≤50 years of age and who had a body mass index
(BMI) <50. Clinical diagnosis of IBS according to the Rome
III criteria: presenting with recurring abdominal pain
or discomfort for at least three days a month in the
last three months that was associated with 2 or more
of the following characteristics: (1) improvement with
defecation, (2) onset associated with a change in stool
frequency, and (3) onset associated with a change in
stool form (appearance). In addition, based on the Rome
III classiﬁcation, patients were categorized according to
bowel habit as IBS-D, IBS-C, IBS-M, and IBS-U. IBS-D was
identiﬁed by loose or liquid stools in at least 25% and
hard or lumpy in less than 25% of bowel movements; IBS-
C: hard or lumpy stools in at least 25% and loose or liquid
r
w
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in less than 25% of bowel movements; IBS-M: hard or
lumpy stools in at least 25% and loose or watery stools in
at least 25% of bowel movements; and IBS-U: modiﬁca-
tions in stool consistency but insufﬁcient to be classiﬁed
as IBS-D, IBS-C, or IBS-M. Active IBS was deﬁned as the
presence of abdominal pain and/or discomfort at least
twice a week during the previous seven days.
b) For exclusion -- The presence of alarm symptoms
over the past 6 months, e.g.: involuntary weight loss,
anorexia, inexplicable anemia, palpable lymph nodes or
masses, fever, digestive tract bleeding, the suspicion or
conﬁrmed presence of malignant disease in any system
or organ; women who were suspected of being pregnant,
women who were pregnant, or who were breastfeed-
ing; the suspicion or conﬁrmed presence of rectoanal
stricture; esophageal varices; a history of chronic non-
speciﬁc ulcerative colitis, Crohn’s disease, or rectoanal
ulcer; major upper or lower abdominal surgery; diges-
tive tract malformation; or bowel obstruction.
esign
n open, prospective, descriptive, and multicenter study
as conducted. Treatment was PB + S for a period of four
eeks. Stool consistency and frequency and improvement
n cardinal symptom intensity (abdominal pain and bloating)
ere evaluated on a weekly basis.
ata collection instrument
he intensity of abdominal pain and bloating were evaluated
y the patients through a 10-cm-long VAS for each symp-
om. Stool consistency (type) was recorded according to the
ristol Stool Scale on a 7-day format that also took into con-
ideration the frequency of all types of bowel movements
Fig. 2). This format, or BM, was used during the four weeks
f treatment. With the BM data, a vectorial calculation was
ade (see the statistical analysis) to evaluate the changes
btained with PB + S treatment.
tatistical analysis
n omnibus variable was created that included two
ariables: consistency (type) and frequency of evacua-
ions obtained from the BM. Given that the aim was to
emonstrate the treatment changes through graphs, a two-
imensional conﬁguration using polar vectors was decided
pon. Polar vectors are dimensionless and can be evaluated
ased on their magnitude, and direction. A vector is a point
n space (it can be multidimensional), that has a distance
rom its point of origin and can move in any direction. Its
oordinates are simply the distance from the origin and the
ngle in relation to a horizontal plane.
The vector calculation was made in the conventional
anner:
√
= x2 + y2,
here r is the magnitude of the vector and y is the equiv-
lent of the hypotenuse of a right triangle and therefore is
24
Bowel movement diary according to the Bristol Stool Scale
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Figure 2 Bowel movement frequency diary according to the
Bristol Stool Scale types (BM). An example of the diary ﬁlled out
by the patients is shown. Drawings of the different stool types
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Tccording to the Bristol Stool Scale are at the top of the diary.
he patients were instructed to identify the type of defecation
nd to mark the frequency of each type daily.
qual to the square root of the sum of the weekly stool fre-
uency (x), plus the total sum of the Bristol Stool Scale types
he patient would have had (y), each one squared. The vec-
orial angle (which is equal to the direction of the vector)
as calculated with the equation:  = tan−1(y/x), in which
an−1 is the arc tangent of the coefﬁcient of the numera-
or y (total sum of the Bristol types) and the denominator x
total weekly stool frequency). Thus, each patient had an r
nd  value that could be lineally combined with the other
ubjects in order to obtain a mean (the expected value)
ector magnitude according to each IBS-Rome III subtype.
he vector was obtained in such a way that it represented
he sum of the variables. In short, the higher the value of
he Bristol type and the frequency of the bowel movements
ere, the greater was the magnitude of the vector. The max-
mum value of x was the result of:
∑n=7
i=1 xi = 28, in a patient
ho would have shown all the Bristol types during the week.
n contrast, the frequency of bowel movements during one
eek determined the maximum value of y. The weekly stool
requency in IBS patients was in the ﬁrst percentile (P1) of 2
efecations, the P10 of 3 defecations, the median (P50) of
defecations, the P90 of 15, the P95 of 19, and the P99 of
8 defecations. In this manner, certain mathematical equiv-
lences are produced that, even though they are not exact,
an be useful for clinical interpretation.
Data were expressed as mean and standard deviation
mean± SD), and standard error (SE) was speciﬁed when
sed. The differences in the means of magnitude and angles
ere calculated with ANOVA for repeated measures and post
oc comparisons were run with the Scheffé test, obtaining
omogeneous groups.thical aspects
he Phase IV clinical study protocol that produced the data
f this analysis was approved by the Ethics Committee of
v
a
o
fJ.C. López-Alvarenga et al.
he Universidad de Guanajuato and the General Hospital of
aucalpan Dr. Maximiliano Ruiz Castan˜eda. The study was
onducted in accordance with the Declaration of Helsinki,5
he Good Clinical Practice,6 and the local regulations con-
erning clinical research. All participating patients signed
nformed consents.
esults
emographic characteristics of the population
he 1677 patients with active IBS included in the clinical
tudy were classiﬁed according to IBS subtype as: IBS-C,
2.9%; IBS-D, 5.6%; IBS-M, 48.6%; and IBS-U, 2.9%. The total
ample mean age was 36.9± 8.8 years, BMI was 26.3± 4.8,
nd 76.8% were women. The percentage of patients who
tated that their IBS progression was longer than one year
as 36.4%. Of the patient total, 1369 (81%) completed the
our weeks of treatment with PB + S and attended their ﬁnal
isit. Table 1 shows the demographic and clinical character-
stics of this subset, according to the IBS subtypes.
ntensity of abdominal pain and bloating
here was a notable reduction in the intensity of abdominal
ain and bloating with the PB + S treatment, regardless of
he IBS subtype. A plateau was not reached at four weeks,
ut there was maximum improvement in that time period
Fig. 3).
ectorial analysis (stool consistency and
requency)
olar vector analysis made it possible to show that there was
onsiderable improvement in the IBS-C patients within the
rst two weeks of treatment and that it remained steady
uring the ﬁnal two weeks. In this group there was an
ncrease in vector magnitude from 10.2 to 12.5, reaching
aximum improvement at two weeks of treatment (p < 0.05,
cheffé). A vector magnitude of 12.5 is apparently equal to
ype 4 on the Bristol Stool Scale.
The magnitude of the vector was reduced in the patients
ith IBS-D and IBS-M. In the IBS-D patients the vector began
t a magnitude of 19.0 and it went toward a magnitude of
4.0 (p < 0.05), whereas the IBS-M group shared the same
irection as the IBS-D group, starting at a magnitude of 16.5
nd gradually moving toward a magnitude of 13.0 (p < 0.05).
here was important improvement in these two IBS subtypes
uring the second treatment week, and unlike the IBS-C
roup, it continued during weeks 3 and 4. The IBS-U group
howed erratic behavior with no deﬁnite pattern in relation
o vector magnitude and direction (Fig. 4).
iscussion
his study demonstrates that the transformation into polar
ectors of the combination of the type of stool consistency
ccording to Bristol Stool Scale, and the frequency of each
f those stool types evaluated in a BM, is a useful method
or evaluating IBS pharmacologic treatments, as it was the
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Table 1 Patient clinical characteristics according to IBS subtype.
IBS-C
(N = 723)
IBS-D
(N = 94)
IBS-M
(N = 812)
IBS-U
(N = 48)
Total
(N = 1677)
p value
Women/men (%) 81.7/18.3 56.4/43.6 74.8/25.2 77.1/22.9 76.8/23.2 <0.01*
Age in years 36.3 (9.0) 37.8 (8.7) 37.3 (8.5) 36.8 (9.0) 36.9 (8.8) 0.13
BMI 26.1 (4.8) 26.9 (4.4) 26.4 (4.8) 26.0 (4.4) 26.3 (4.8) 0.39
Heart rate×min 75.8 (7.4) 76.6 (7.3) 76.6 (7.7) 76.3 (7.8) 76.3 (7.6) 0.19
Respiratory rate×min 18.8 (3.0) 19 (3.0) 19 (3.0) 18.2 (3.0) 18.9 (3.0) 0.29
Systolic BP (mmHg) 115 (10.0) 118 (13.0) 116 (11.0) 117 (12.0) 116 (11.0) 0.08
Diastolic BP (mmHg) 74 (8.0) 76 (7.0) 74 (7.0) 74 (8.0) 74 (8.0) 0.34
BMI: body mass index; min: minutes; BP: blood pressure. Data expresse
* Contrast carried out with 2 = 33.8, gl = 8. The remaining contrasts
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Figure 3 Changes in the intensity of abdominal pain and
bloating. The intensity of abdominal pain and bloating was eval-
uated by the patients through a 10 cm VAS. The changes in
time were signiﬁcant (p < 0.001, repeated measures MANOVA)
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afor pain (A) and bloating (B). The contrast between subtypes
showed no signiﬁcant difference. Blue: IBS-C, red: IBS-D, green:
IBS-M, and pink: IBS-U. The ﬁgure shows means± SE.
case with PB + S. This approach to evaluate efﬁcacy does
not include the changes in IBS cardinal symptoms, such as
abdominal pain and bloating, because they can be evaluated
through VAS.
Polar vector analysis clearly displayed the difference in
treatment response in the various IBS subtypes, according
o
t
a
rd as mean (standard deviation).
were carried out through one-way ANOVA.
o the predominant bowel habit. Even though all the sub-
ypes responded positively to PB + S treatment, the response
as different for each one. IBS-C showed a rapid symptom
esponse within the ﬁrst two weeks and then remained sta-
ionary, while improvement was progressive in IBS-D and
BS-M and continued to advance up to four weeks. According
o the angle followed by the vectors on the polar coordi-
ate plane (near 45◦), bowel movement improvement was
roportional in both consistency and frequency, without
avoring either of the two variables. Upon graphing the polar
ectors it became obvious that, despite the direction of
he improvement of each IBS subtype, they all appeared to
dvance toward a common zone located between points 12.5
nd 14, in relation to stool consistency and frequency; this
one could represent ‘‘normalcy’’ and such a ﬁnding needs
o be veriﬁed in future studies.
A current limitation in the development of new IBS ther-
peutic options is the lack of validated outcome measures
hat objectively record their efﬁcacy in clinical studies7; the
act that there are no biological markers for the diagnosis of
BS also has to be taken into account.8 In the last few years,
he most widely used primary outcome measures in IBS clin-
cal studies have been global variables of binary response:
dequate improvement of abdominal pain and discomfort
r satisfactory relief of IBS symptoms, that followed the
ome recommendations.9 Nevertheless, certain psychome-
ric aspects of these variables have not been adequately
alidated and therefore are not presently accepted by the
egulatory agencies.3 This has led to continuous meetings
etween the representatives of those agencies, experts on
he subject matter, and representatives of the pharmaceu-
ical industry,2 in an effort to deﬁne the reported outcome
easures for the patients, the so-called PRO or Patient
eported Outcomes.2 This can be difﬁcult when it entails
valuating the results in patients with FGIDs that do not
ave an organic or structural lesion and whose evaluation
s made through symptom-based criteria.10,11
The method of analysis used in this study has taken
he current tendencies and recommendations into account,
uch as including diagnosed patients through the Rome III
riteria1 and evaluating the changes in stool consistency
nd frequency. In addition, it was based on the collection
f symptoms through diaries and the weekly evaluation of
reatment response. It also contemplated the variables in
multidimensional context and evaluated the individual
esponse in the different IBS subtypes.3
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ihe magnitude of the vector, there is overlapping in the IBS-D, I
cheffé groups in the post hoc analysis. See the statistical anal
A ﬁrst limitation of the suggested method is the fact that
he physician must graph the weekly vector results himself
owever, it is possible to develop computerized programs
hat can facilitate the follow-up of changes that occur in
he patients and that can show the results of different treat-
ents. A second limitation is that this method is applicable
xclusively to medications that have an effect on stool con-
istency and frequency, and as a result, a third limitation
s the fact that polar vectors do not evaluate the effect
f treatment on abdominal pain or discomfort (abdominal
loating) that are key symptoms in IBS. However, it is worth
oting that a recent review of the literature on question-
aires used in IBS to create a framework by which PRO can be
eveloped for this disorder, established that abdominal pain
nd discomfort are two different symptoms. Therefore ques-
ions about discomfort response should be avoided, because
t is very nonspeciﬁc.12 In the future, evaluations will have to
e made on whether improvement in stool consistency and
requency not only reduces abdominal pain, but also other
ymptoms such as associated anxiety,13 and also whether the
ffect on pain and anxiety can be analyzed through vec-
ors. A fourth limitation of this study is that the clinical
igniﬁcance of the change in vector magnitude and direc-
ion has not been determined. Regulatory agencies have
mphasized the importance of identifying objective end-
oints that would allow clinically signiﬁcant improvement to
F
T, and the IBS-U spaces. The letters correspond to homogeneous
ection for details.
e established, and thus report the percentage of patients
hat manage to go beyond that endpoint.2 Finally, the vecto-
ial method was studied in patients who were seen in private
edical practices in Mexico and it is necessary not only to
alidate the results in studies on open populations, but also
n subjects from other cultures and in other languages.
In conclusion, polar vectors can be useful in clinical trials
or the integral evaluation of the changes in stool con-
istency and frequency in response to an IBS treatment.
ectorial analysis shows that the combined therapy of PB + S,
dministered for at least four weeks, differentially modiﬁes
he frequency and consistency of bowel movements in all IBS
ubtypes, but with differences in the magnitude and velocity
f the change between them. It should be pointed out that,
ven though the polar vectors analyzed in this study did not
valuate the response to pain and/or subjective abdomi-
al bloating, the improvement of these symptoms analyzed
hrough VAS was also signiﬁcant for all the IBS subtypes. It
s necessary to apply this method of analysis in placebo-
ontrolled studies in order to conﬁrm the results observed
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